Tarbox Family Office’s AMAG Pharmaceuticals AMAG Stock Holding History

Tarbox Family Office’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-209	Closed	-$3K	–	1401
2019 Q4	$3K	Hold	209	–	–	﹤0.01%	744
2019 Q3	$2K	Buy	+209	New	+$2.2K	﹤0.01%	836

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tarbox Family Office's AMAG Position: Q1 2020 in Review

Tarbox Family Office sold out of AMAG Pharmaceuticals (AMAG) in Q1 2020, closing a stake of 209 shares — an estimated $3K sold.

Tarbox Family Office first reported a position in AMAG in Q3 2019 and held it in 2 quarters. The position peaked at $3K in Q4 2019. 119 funds tracked by Wall St. Rank hold AMAG as of Q1 2020.

Tarbox Family Office reported no remaining AMAG Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Tarbox Family Office sold 209 AMAG Pharmaceuticals shares in Q1 2020, an estimated $3K.
Tarbox Family Office first reported a position in AMAG Pharmaceuticals in Q3 2019 and held it in 2 quarters.
Tarbox Family Office's AMAG Pharmaceuticals position peaked at $3K in Q4 2019.
119 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2020.

Based on Tarbox Family Office's 13F filing for Q1 2020, filed 30 Apr 2020.